WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 21-Sep-2018 (data as of 18-Sep-2018)
Next overall update spring 2019
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 40'5301 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 43'8771 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 66'182  65'789  65'397  65'016  64'641  58'951  57'183  56'265 
Births 806  806  805  805  804  696  779  687 
Surviving infants 804  803  802  802  800  692  773  678 
Pop. less than 5 years 3'999  4'000  4'043  4'049  4'072  3'553  3'826  3'384 
Pop. less than 15 years 11'722  11'591  11'500  11'401  11'337  11'222  10'843  11'825 
Female 15-49 years 14'789  14'862  14'924  14'992  15'048  14'149  14'134  13'142 

Number of reported cases

(Click for retrospective incidence data for United Kingdom of Great Britain and Northern Ireland (the))
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  364  558  91  133  1'919  104  28'228  147'962 
Mumps
ChartChart
  2'360  974  1'008  2'958  4'718  1'089 
Pertussis
ChartChart
  5'097  7'085  5'207  4'046  6'090  866  16'605  22'924 
Polio*
ChartChart
 
Rubella
ChartChart
  15  13  75 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  18  30 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          94  94  95  95  95  91  85 
DTP4          87  87  89  90 
IPV1         
HepB_BD         
HepB3         
Hib3          94  94  95  95  95  91 
JapEnc         
MCV1          92  92  93  93  93  88  89 
MCV2          88  89  89  89  88  76 
MenA         
PCV1         
PCV2          94  94  94  95  96 
PCV3          92  92  93  93  93 
Pol3          94  94  95  95  95  91  90 
Rota1         
RotaC          90  90  89 
RCV1          92  92  93  93  95 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
DTP1
ChartChart
  98  98  98  98  98  97  94  66 
DTP3
ChartChart
  94  94  95  95  95  91  84  41 
HepB3
 
HepB_BD
 
Hib3
ChartChart
  94  94  95  95  95  91 
MCV1
ChartChart
  92  92  93  93  93  88  87  53 
MCV2
ChartChart
  88  89  89  89  88  76 
PCV3
  92  92  93  93  93 
Pol3
  94  94  95  95  95  91  92  81 
RCV1
ChartChart
  92  92  93  93  93  88  87  53 
RotaC
ChartChart
  90  90  89 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 175  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 88
From 80 to 89% 10
From 50 to 79% 2
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes at birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country
DTaPHibHepBIPV 8, 12, 16 weeks; Yes from August 2017
DTaPHibIPV 8, 12, 16 weeks; Yes until August 2017
DTaPIPV 3 years and 4 months; Yes and pregnant women from 16 weeks
HepB_Pediatric birth; 4, 8 weeks; 1 year; Yes high risk groups only; from August 2017 offered at birth, 4 weeks and 1 year only
HibMenC 1 year; Yes
HPV 12-13 years; +6-24 months; Yes females only
Influenza_Adult >=65 years; Yes and adults with chronic illness, pregnant women, health care workers, residents living in long-term care facilities, other risk groups
Influenza_Pediatric 2-5 years; Yes and children with chronic illness
MenACWY-135 conj 14, 18-25 years; Yes offered to adolescents and University Freshers up to the age of 25
MenB 8, 16 weeks; 1 year; Yes
MenC_conj 12 weeks; Yes
MMR 12 months; 3 years and 4 months; Yes additional screening offered to susceptible women identified through antenatal services
Pneumo_conj 8, 16 weeks; 1 year; Yes
Pneumo_ps >=65 years; Yes and at risk groups from 2-65 years
Rabies 1st contact; 7, 28 days; Yes for individuals at continous & frequent risk of exposure to Rabies virus
Rotavirus 8, 12 weeks; Yes
TdIPV 14 years; Yes
Varicella Yes non-immune individuals working with susceptible patients
Zoster 70, 78 years; Yes

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 5 years from current year (i.e. 2018/19 to 2022/23)  2016-2020  2017-2018         
Nº of districts with microplans that include activities to raise immunization coverage number 221  221      151  152  151 

System performance

Total Nº districts in country number 175      174  176  176  421 
Nº districts with DTP3 coverage >=80% number 171  173  172  172  175  176  176 
% of districts with DTP3 coverage >=80% From 0 to 100% 98      99  99  100  42 
Nº districts with measles (MCV1) coverage >=95% number 55  61  74  89  67  33 
% of districts with MCV1 coverage >=95% From 0 to 100% 31      51  38  19 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.